MAIA Biotechnology Reports 2+ Year Overall Survival In Eight Patients From Ongoing Phase 2 NSCLC Trial

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new data from a poster presented on March 27, 2026, at the European Lung Cancer Congress (ELCC) in Copenhagen, Denmark. The presentation summarized encouraging survival results from Parts A and B of the company’s ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC).

According to the update, eight patients treated with ateganosine followed by cemiplimab achieved overall survival beyond two years without receiving any additional therapy after their participation in the trial. The results are especially notable because all eight patients had previously failed checkpoint inhibitor treatment before joining THIO-101.

The poster highlighted specific details about these patients. One patient treated in the third-line setting has reached 33 months of survival, compared with an expected 5.8 months for individuals typically treated at this stage. Additionally, four patients treated in the second-line setting have now survived more than 30 months. In comparison, patients receiving standard second-line therapies such as chemotherapy or checkpoint inhibitors alone typically experience median overall survival of about 10.5 months. Most of the patients completed between 29 and 34 cycles of the treatment sequence, except one who stopped after two cycles but continues to have survival follow-up reaching 725 days off therapy. Five of the eight patients are still being followed.

MAIA’s Founder and CEO, Dr. Vlad Vitoc, said these long-term results are highly encouraging and extend well beyond the original 24-month protocol. He explained that the durability of survival, achieved without further treatment, supports the growing potential of ateganosine as part of a new therapeutic approach for NSCLC. He added that the findings help confirm ateganosine’s mechanism of targeting telomeres to destroy tumor cells, further strengthening the rationale for sequencing ateganosine with a checkpoint inhibitor such as cemiplimab as a promising treatment option.

The THIO-101 trial enrolled a total of 79 patients in its first two parts. The study is now continuing with Part C, which is enrolling up to 48 additional participants across Asia and Europe. So far, treatment with ateganosine followed by cemiplimab (Libtayo) has shown an acceptable safety profile even in patients who have already undergone multiple previous therapies. MAIA plans to continue following patients in the Phase 3 pivotal trial and in Part C to build a more complete picture of the long-term benefits of this treatment approach.